CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

Adenocaine solutions from CAPS arrive prelabeled with CAPS high-contrast labeling to maximize legibility and usability in the operating room, and with tamper evidence for added safety.

"When it comes to high-quality service, CAPS delivers. That means Adenocaine users will now have reliable, convenient and consistent access to our solutions whenever they need them," said David C. Field, Chief Executive Officer for Hibernation Therapeutics. "State-of-the-art cleanroom technology and more than 15 years of experience in the cardioplegia solution market make CAPS the ideal provider of Adenocaine preparations."

CAPS offers the industry's widest range of service options, including same day and next day delivery, 365 days a year.

"We're excited to offer this unique, proprietary, patented solution and service to the cardioplegia market," said Todd Jones, Director of Marketing for CAPS. "Our quality focus and high level of service will complement the innovative solutions from Hibernation Therapeutics."

CAPS meets or exceeds USP Chapter <797> guidelines to safely deliver high-quality admixtures to hospitals from coast to coast.

Source:

B. Braun

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 20). CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia. News-Medical. Retrieved on April 02, 2020 from https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx.

  • MLA

    B. Braun Melsungen AG. "CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia". News-Medical. 02 April 2020. <https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx>.

  • Chicago

    B. Braun Melsungen AG. "CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia". News-Medical. https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx. (accessed April 02, 2020).

  • Harvard

    B. Braun Melsungen AG. 2019. CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia. News-Medical, viewed 02 April 2020, https://www.news-medical.net/news/20100423/CAPS-launches-new-service-for-admixture-and-delivery-of-Hibernation-Therapeutics-Adenocaine-microplegia.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System